MBX Biosciences Announces Proposed Public Offering
MBX Biosciences (Nasdaq: MBX), a clinical-stage biopharmaceutical company specializing in precision peptide therapies for endocrine and metabolic disorders, has announced a proposed public offering of 10 million shares of common stock. The company will also grant underwriters a 30-day option to purchase up to an additional 1.5 million shares.
The offering will be managed by J.P. Morgan, Jefferies, TD Cowen, and Guggenheim Securities as joint book-running managers, with Citizens Capital Markets and Oppenheimer & Co. serving as co-lead managers. The public offering price has not yet been determined, and the offering is subject to market conditions and SEC registration effectiveness.
MBX Biosciences (Nasdaq: MBX), una società biofarmaceutica in fase clinica specializzata in terapie peptidiche di precisione per disturbi endocrini e metabolici, ha annunciato una proposta di offerta pubblica di 10 milioni di azioni ordinarie. L'azienda concederà anche agli underwriter un'opzione di 30 giorni per acquistare fino a un ulteriore 1,5 milioni di azioni.
L'offerta sarà gestita da J.P. Morgan, Jefferies, TD Cowen e Guggenheim Securities come co-responsabili della gestione, con Citizens Capital Markets e Oppenheimer & Co. a servire come co-lead managers. Il prezzo di offerta pubblica non è stato ancora determinato, e l'offerta è soggetta alle condizioni di mercato e all'efficacia della registrazione SEC.
MBX Biosciences (Nasdaq: MBX), una compañía biofarmacéutica en fase clínica que se especializa en terapias de péptidos de precisión para trastornos endocrinos y metabólicos, ha anunciado una oferta pública propuesta de 10 millones de acciones ordinarias. La empresa también otorgará a los underwriters una opción de 30 días para comprar hasta un adicional 1,5 millones de acciones.
La oferta será gestionada por J.P. Morgan, Jefferies, TD Cowen y Guggenheim Securities como gerentes de libro conjuntos, con Citizens Capital Markets y Oppenheimer & Co. como co-líderes. El precio de venta en la oferta pública aún no se ha determinado, y la oferta está sujeta a condiciones de mercado y a la eficacia de la registración ante la SEC.
MBX Biosciences (나스닥: MBX)은 내분비 및 대사 질환에 대한 정밀 펩타이드 치료에 특화된 임상 단계 생물의약 회사로, 10백만 주의 공개 공개발행(제안 공모)를 발표했습니다. 또한 회사는 인수단에 30일 옵션을 부여하여 추가로 최대 150만 주를 매입할 수 있게 합니다.
공모는 J.P. 모건, 제퍼리스, TD 카웬, 그리고 구겐하임 시큐리티스가 공동북런너로 관리하고, Citizens Capital Markets와 Oppenheimer & Co.가 공동리드 매니저로 역할합니다. 공모 가격은 아직 결정되지 않았으며, 공모는 시장 상황과 SEC 등록의 효력에 따라 달라집니다.
MBX Biosciences (Nasdaq: MBX), une société biopharmaceutique en phase clinique spécialisée dans les thérapies peptidiques de précision pour les troubles endocriniens et métaboliques, a annoncé une offre publique proposée de 10 millions d'actions ordinaires. L'entreprise accordera également aux souscripteurs une option de 30 jours d'acheter jusqu'à un supplément 1,5 million d'actions.
L'offre sera gérée par J.P. Morgan, Jefferies, TD Cowen, et Guggenheim Securities en tant que syndicat de placement global, Citizens Capital Markets et Oppenheimer & Co. agissant en tant que co-chefs de placement. Le prix de l'offre publique n'a pas encore été determiné et l'offre est soumise aux conditions de marché et à l'efficacité de l'enregistrement auprès de la SEC.
MBX Biosciences (Nasdaq: MBX), ein in klinischer Entwicklung befindliches Biopharma-Unternehmen, das sich auf präzise Peptidtherapien für endokrine und metabolische Erkrankungen spezialisiert hat, hat eine vorgeschlagene öffentliche Emission von 10 Millionen Aktien angekündigt. Das Unternehmen wird unterwritern auch eine 30-tägige Option einräumen, bis zu zusätzlichen 1,5 Millionen Aktien zu zeichnen.
Das Angebot wird von J.P. Morgan, Jefferies, TD Cowen und Guggenheim Securities als gemeinsame Book-Running-Manager geleitet, Citizens Capital Markets und Oppenheimer & Co. fungieren als Co-Lead-Manager. Der öffentliche Angebotspreis ist noch nicht festgelegt, und das Angebot unterliegt den Marktbedingungen und der Wirksamkeit der SEC-Registrierung.
MBX Biosciences (ناسداك: MBX)، شركة الأدوية الحيوية في مرحلة سريرية والمتخصصة في علاجات الببتيدات الدقيقة للاضطرابات الغددية والاستقلابية، أعلنت عن عرض عام مقترح لـ10 ملايين سهم من الأسهم العادية. ستمنح الشركة أيضاً للمكتتبين خياراً لمدة 30 يوماً لشراء حتى 1.5 مليون سهم إضافي.
سيتم إدارة العرض من قبل J.P. مورغان، جيفريز، TD كوون، وجوغنهايم سيكيوريتس كمديرين مشتركين للكتاب، فيما تعمل Citizens Capital Markets و Oppenheimer & Co. كمشرفين مشاركين. لم يتم تحديد سعر العرض العام بعد، والعرض خاضع لظروف السوق وفعالية تسجيل هيئة الأوراق المالية الأمريكية.
MBX Biosciences（纳斯达克：MBX），一家专注于内分泌与代谢疾病精准肽治疗的临床阶段生物制药公司，宣布<拟公开发行1000万股普通股。公司还将授予承销商30天的选择权，最多购买额外的150万股。
本次发行将由摩根大通、Jefferies、TD Cowen 和 Guggenheim Securities共同承销管理，Citizens Capital Markets和Oppenheimer & Co.担任共同主承销商。公开发行价格尚未确定，发行受市场条件和美国证券交易委员会注册生效的约束。
- Potential to raise significant capital for company operations and development
- Strong lineup of reputable investment banks as underwriters
- Potential dilution for existing shareholders
- Timing of offering during market uncertainty could affect pricing
Insights
MBX Biosciences plans to raise capital through a 10M share offering with potential dilution impact for existing shareholders.
MBX Biosciences has filed for a significant public offering of 10,000,000 shares of common stock, with an additional 1,500,000 shares potentially available to underwriters through a 30-day option. This capital-raising initiative comes as the company continues to develop its pipeline of precision peptide therapies targeting endocrine and metabolic disorders.
The offering's pricing hasn't been determined yet, indicating the company is likely gauging market interest before finalizing terms. This approach allows flexibility in responding to investor sentiment and current market conditions. The involvement of major financial institutions as joint book-running managers - J.P. Morgan, Jefferies, TD Cowen and Guggenheim Securities - suggests institutional confidence in the offering.
For existing shareholders, this offering likely represents potential dilution of their ownership stakes. While the capital infusion could accelerate MBX's clinical development programs and extend its operational runway, investors should consider how the increased share count might impact per-share metrics.
As a clinical-stage biopharmaceutical company without marketed products, MBX relies on periodic capital raises to fund ongoing operations and research. This offering appears to be a strategic move to strengthen the company's financial position while pursuing its development pipeline, though the ultimate impact will depend on the final pricing and how effectively management deploys the new capital.
CARMEL, Ind., Sept. 22, 2025 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders, today announced that it has filed a registration statement on Form S-1 with the U.S. Securities and Exchange Commission (SEC) relating to a proposed underwritten public offering of 10,000,000 shares of its common stock. Furthermore, MBX Biosciences intends to grant the underwriters a 30-day option to purchase from MBX Biosciences up to an additional 1,500,000 shares of its common stock at the public offering price, less underwriting discounts and commissions. The public offering price has not yet been determined. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed or as to the actual size or terms of the offering.
J.P. Morgan, Jefferies, TD Cowen and Guggenheim Securities are acting as joint book-running managers for the offering. Citizens Capital Markets and Oppenheimer & Co. are acting as co-lead managers for the offering.
A registration statement on Form S-1 relating to the proposed offering has been filed with the SEC but has not yet become effective. A copy of the registration statement can be accessed through the SEC’s website at www.sec.gov. These securities may not be sold, nor may offers to buy be accepted, prior to the time the registration statement becomes effective.
The proposed offering is being made only by means of a prospectus. Copies of the preliminary prospectus relating to the offering may be obtained from: J.P. Morgan Securities LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by email at prospectus-eq_fi@jpmchase.com and postsalemanualrequests@broadridge.com; Jefferies LLC, Attn: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, New York 10022, by telephone at (877) 821-7388 or by email at Prospectus_Department@Jefferies.com; TD Securities (USA) LLC, 1 Vanderbilt Avenue, New York, NY 10017, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 or by email at TDManualrequest@broadridge.com; Guggenheim Securities, LLC, Attention: Equity Syndicate Department, 330 Madison Avenue, New York, NY 10017, telephone: (212) 518-9544, email: GSEquityProspectusDelivery@guggenheimpartners.com.
This press release shall not constitute an offer to sell, or the solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation, or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.
About MBX Biosciences
MBX Biosciences is a biopharmaceutical company focused on the discovery and development of novel precision peptide therapies based on its proprietary PEP™ platform, for the treatment of endocrine and metabolic disorders. The Company is advancing a pipeline of novel candidates for endocrine and metabolic disorders with clinically validated targets, established endpoints for regulatory approval, significant unmet medical needs and large potential market opportunities.
Forward-Looking Statements
This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, each as amended. The words “anticipate,” “believe,” “continue,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “would” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. These forward-looking statements include, but are not limited to, express or implied statements regarding: MBX Biosciences’ expectations regarding the consummation, timing and size of the offering and the grant of the option to purchase additional shares to the underwriters.
Forward-looking statements are based on management’s current expectations and are subject to risks and uncertainties that could negatively affect MBX Biosciences’ business, operating results, financial condition and stock value. Factors that could cause actual results to differ materially from those currently anticipated include risks and uncertainties related to market conditions, satisfaction of customary closing conditions related to the offering as well as other risks described in “Risk Factors,” in MBX Biosciences’ Annual Report on Form 10-K for the year ended December 31, 2024 filed with the Securities and Exchange Commission (SEC), its Quarterly Report on Form 10-Q for the quarter ended June 30, 2025 filed with the SEC, as well as subsequent filings with the SEC. MBX Biosciences expressly disclaims any obligation or undertaking to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in its expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law, and claims the protection of the safe harbor for forward-looking statements contained in the Private Securities Litigation Reform Act of 1995.
Media Contact:
Katie Beach Oltsik
Inizio Evoke Comms
katie.beach@inizioevoke.com
(937) 232-4889
Investor Contact:
Jim DeNike
MBX Biosciences
jdenike@mbxbio.com
FAQ
How many shares is MBX Biosciences offering in its proposed public offering?
Who are the underwriters for MBX Biosciences' public offering?
What is the price per share for MBX Biosciences' public offering?
What type of company is MBX Biosciences?
How can investors participate in MBX Biosciences' public offering?
